PHARMACEUTICAL COMPOSITION OF A TRILAYER TABLET FOR THE TREATMENT OF DIABETES MELLITUS

Patent Pending The present invention provides methods for preparing trilayer tablet compositions and methods for treating diseases and disorders associated with SGLT2 activity using trilayer tablet compositions.Metformin may be in the form of a pharmaceutically acceptable salt, where metformin hydrochloride (HCl) is preferred. A preferred SGLT2 inhibitor are dapagliflozin or a pharmaceutically acceptable salt thereof, dapagliflozin (S) propylene glycol hydrate (1: 1: 1) or dapagliflozin (R) propylene glycol hydrate (1: 1: 1) and empagliflozin. The SGLT2 inhibitors composition is an immediate release composition or a sustained release composition, wherein an immediate release composition is preferred.